Beatrolol

Heart Disorder

University of Sao PauloSmall moleculePhase 3Dormant

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 95/ 100

Competitive context

14 Active assets in the Heart Disorder cohort.

Asset / Sponsor	Phase	Rating
Potassium Tufts Medical Center	Phase 3	BB
Orlistat University of British Columbia	Phase 4	BB
Warfarin Massachusetts General Hospital	Phase 3	BB
Acoramidis Eidos Therapeutics, a BridgeBio company	Phase 3	BB
Carvedilol Abramson Cancer Center at Penn Medicine	Phase 3	BB

View all 34 →

Same molecule, other indications

Beatrolol is also rated in:

cardiomyopathyDormant

B

Indicative · Phase 3

60 / 100

beta thalassemiaDormant

B

Indicative · Phase 2/3

58 / 100

abdominal obesity-metabolic syndromeDormant

B

Indicative · Phase 4

58 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.